» Articles » PMID: 16387467

Long Term Treatment Related Upper Limb Morbidity and Quality of Life After Sentinel Lymph Node Biopsy for Stage I or II Breast Cancer

Overview
Publisher Elsevier
Date 2006 Jan 3
PMID 16387467
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In a prospective study, long term upper-limb morbidity, perceived disabilities in activities of daily life (ADL) and quality of life (QOL) were assessed before and 2 years after sentinel lymph node biopsy (SLNB) or axillary lymph node dissections (ALND) for breast cancer.

Methods: Two hundred and four patients with stage I/II breast cancer, mean age 55.6 years (SD: 11.6) entered the study and 181 patients (89%) could be evaluated after 2 years. Fifty-seven patients underwent SLNB (31%) and 124 patients underwent an ALND (69%). Assessments included pain, shoulder range of motion, muscle strength, arm volume, perceived shoulder disability in ADL and QOL.

Results: Significant (P<0.05) changes between before and 2 years after surgery were found in almost all assessments of shoulder function, ADL and several QOL subscales. Patients in the ALND group showed significant more changes in range of motion (ROM), grip strength, arm volume, ADL and QOL physical- and role functioning, pain and sleeplessness and arm symptoms compared to the SLNB group. Multivariate linear regression analysis showed that ALND could predict decrease of ROM, grip strength, ADL and physical functioning (QOL) and increase of arm volume, pain and arm symptoms score (QOL). Radiation on the axilla predicts an additional decrease in shoulder ROM and increase of arm volume.

Conclusion: Two years after surgery for breast cancer, patients show significantly less treatment related upper limb morbidity, perceived disability in ADL and worsening of QOL after SLNB compared with ALND.

Citing Articles

Prognostic factors for the development of upper limb dysfunctions after breast cancer: the UPLIFT-BC prospective longitudinal cohort study protocol.

De Groef A, Vets N, Devoogdt N, Smeets A, Van Assche D, Emmerzaal J BMJ Open. 2024; 14(5):e084882.

PMID: 38754876 PMC: 11097819. DOI: 10.1136/bmjopen-2024-084882.


Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort.

Cogollos-de-la-Pena R, Alvarez-Vargas A, Dominguez-Navarro F, Espelt A, Fuentes-Aparicio L, Puigpinos-Riera R Breast Cancer Res Treat. 2023; 204(2):377-387.

PMID: 38155271 PMC: 10948522. DOI: 10.1007/s10549-023-07191-9.


Single-port endoscopic-sentinel lymph node biopsy combined with indocyanine green and carbon nanoparticles in breast cancer.

Wang Z, Gang T, Wu S, Lu C, Gao G, Xu W Surg Endosc. 2023; 37(10):7591-7599.

PMID: 37460818 PMC: 10520094. DOI: 10.1007/s00464-023-10018-9.


Measuring upper limb function and patient reported outcomes after major breast cancer surgery: a pilot study in an Asian cohort.

Chan K, Zeng D, Leung J, Ooi B, Kong K, Yeo Y BMC Surg. 2020; 20(1):108.

PMID: 32430021 PMC: 7236525. DOI: 10.1186/s12893-020-00773-0.


A quantitative comparison of arm activity between survivors of breast cancer and healthy controls: use of accelerometry.

Fisher M, Davies C, Uhl T Support Care Cancer. 2020; 28(11):5307-5313.

PMID: 32112354 DOI: 10.1007/s00520-020-05365-5.